NCT lookup

Inclusion Criteria:

* Signed, informed consent form
* Age 18 to 50 years old (inclusive)
* Diagnosis of MS per update of McDonald criteria, and cranial MRI scan demonstrating white matter lesions attributable to MS within 10 years of screening
* Onset of MS symptoms within 15 years of screening
* Neurostatus (EDSS) score 0.0 to 5.0 (inclusive)
* 2 MS attacks (first episode or relapse) occurring in the 24 months prior to screening, with 1 attack in the 12 months prior to screening, with objective neurological signs confirmed by a physician.

Exclusion Criteria:

* Received prior therapy for MS other than corticosteroids within 28 days of screening; e.g., interferon's, IV immunoglobulin, and glatiramer acetate
* Exposure to natalizumab within 6 months of screening
* Any prior exposure to mitoxantrone, mycophenolate mofetil, azathioprine, cladribine, cyclophosphamide, cyclosporine A, methotrexate, rituximab, or any other immunosuppressive agent other than systemic corticosteroid treatment
* Has any progressive form of MS
* History of malignancy (exception for basal cell skin carcinoma)
* Previous hypersensitivity reaction to other immunoglobulin product
* Intolerance of pulsed corticosteroids, especially a history of steroid psychosis
* CD4+, CD8+, or CD19+ (i.e., absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3) count \<LLN at Screening; if abnormal cell count(s) return to within normal limits, eligibility may be reassessed
* Seropositivity for human immunodeficiency virus (HIV)
* Significant autoimmune disease (e.g, immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders; vasculitis; inflammatory bowel disease; severe psoriasis)
* Presence of anti-thyroid stimulating hormone (TSH) receptor (TSHR) antibodies
* Active infection
* Latent tuberculosis unless effective anti-tuberculosis therapy has been completed, or active tuberculosis.
* Infection with hepatitis B virus or hepatitis C virus
* Of childbearing potential with a positive serum pregnancy test
* Unwilling to agree to use a reliable and acceptable contraceptive method throughout the study period
* Major psychiatric disorder that is not adequately controlled by treatment
* Epileptic seizures that are not adequately controlled by treatment
* Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results
* Medical, psychiatric, cognitive, or other conditions
* Confirmed platelet count the lower limit of normal (LLN) of the evaluating laboratory at Screening or documented at 100,000/L within the past year on a sample without clumping
* Prior history of invasive fungal infections
* Cervical high risk human papilloma virus (HPV) positivity or abnormal cervical cytology other than abnormal squamous cells of undetermined significance (ASCUS).
* Seropositive for Trypanosoma cruzi or the Human T-lymphotropic virus type I or type II (HTLV-I/II) (testing required in endemic regions only)
* Any other illness or infection (latent or active) that, in the Investigator's opinion, could be exacerbated by alemtuzumab treatment
* Any hepatic or renal function value grade 2 or higher at Screening, with the exception of hyperbilirubinemia due to Gilbert's syndrome.

• Vancouver, British Columbia, Canada